Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry.

Slavicek L, Pavlik T, Tomasek J, Bortlicek Z, Buchler T, Melichar B, Vyzula R, Prausova J, Finek J, Majek O, Dusek L.

BMC Gastroenterol. 2014 Mar 25;14:53. doi: 10.1186/1471-230X-14-53.

2.

Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis.

Buchler T, Pavlik T, Melichar B, Bortlicek Z, Usiakova Z, Dusek L, Kiss I, Kohoutek M, Benesova V, Vyzula R, Abrahamova J, Obermannova R.

BMC Cancer. 2014 May 7;14:323. doi: 10.1186/1471-2407-14-323.

3.

Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.

Boisen MK, Johansen JS, Dehlendorff C, Larsen JS, Osterlind K, Hansen J, Nielsen SE, Pfeiffer P, Tarpgaard LS, Holländer NH, Keldsen N, Hansen TF, Jensen BB, Jensen BV.

Ann Oncol. 2013 Oct;24(10):2554-9. doi: 10.1093/annonc/mdt253. Epub 2013 Jul 17.

PMID:
23864097
4.

Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).

Schmoll HJ, Cunningham D, Sobrero A, Karapetis CS, Rougier P, Koski SL, Kocakova I, Bondarenko I, Bodoky G, Mainwaring P, Salazar R, Barker P, Mookerjee B, Robertson J, Van Cutsem E.

J Clin Oncol. 2012 Oct 10;30(29):3588-95. doi: 10.1200/JCO.2012.42.5355. Epub 2012 Sep 10.

PMID:
22965961
5.

Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study.

Bendell JC, Bekaii-Saab TS, Cohn AL, Hurwitz HI, Kozloff M, Tezcan H, Roach N, Mun Y, Fish S, Flick ED, Dalal D, Grothey A.

Oncologist. 2012;17(12):1486-95. doi: 10.1634/theoncologist.2012-0190. Epub 2012 Sep 26.

6.

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.

Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, Mazier MA, Canon JL, Georgoulias V, Peeters M, Bridgewater J, Cunningham D; First BEAT investigators.

Ann Oncol. 2009 Nov;20(11):1842-7. doi: 10.1093/annonc/mdp233. Epub 2009 Apr 30.

PMID:
19406901
7.

Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial.

Passardi A, Nanni O, Tassinari D, Turci D, Cavanna L, Fontana A, Ruscelli S, Mucciarini C, Lorusso V, Ragazzini A, Frassineti GL, Amadori D.

Ann Oncol. 2015 Jun;26(6):1201-7. doi: 10.1093/annonc/mdv130. Epub 2015 Mar 3.

PMID:
25735317
8.

The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab.

Budai B, Nagy T, Láng I, Hitre E.

Angiogenesis. 2013 Jan;16(1):113-21. doi: 10.1007/s10456-012-9303-z. Epub 2012 Sep 6.

PMID:
22956187
9.

Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab.

Liu Y, Starr MD, Bulusu A, Pang H, Wong NS, Honeycutt W, Amara A, Hurwitz HI, Nixon AB.

Cancer Med. 2013 Apr;2(2):234-42. doi: 10.1002/cam4.71. Epub 2013 Mar 6.

10.

Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer.

Feliu J, Salud A, Safont MJ, García-Girón C, Aparicio J, Losa F, Bosch C, Escudero P, Casado E, Jorge M, Bohn U, Pérez-Carrión R, Carmona A, Custodio AB, Maurel J.

PLoS One. 2015 Jan 20;10(1):e0116527. doi: 10.1371/journal.pone.0116527. eCollection 2015.

11.

Primary Tumour Resection Could Improve the Survival of Unresectable Metastatic Colorectal Cancer Patients Receiving Bevacizumab-Containing Chemotherapy.

Wang Z, Liang L, Yu Y, Wang Y, Zhuang R, Chen Y, Cui Y, Zhou Y, Liu T.

Cell Physiol Biochem. 2016;39(3):1239-46. doi: 10.1159/000447829. Epub 2016 Sep 5.

12.

Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).

Hoff PM, Hochhaus A, Pestalozzi BC, Tebbutt NC, Li J, Kim TW, Koynov KD, Kurteva G, Pintér T, Cheng Y, van Eyll B, Pike L, Fielding A, Robertson JD, Saunders MP.

J Clin Oncol. 2012 Oct 10;30(29):3596-603. doi: 10.1200/JCO.2012.42.6031. Epub 2012 Sep 10.

PMID:
22965965
13.

Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view.

Bencsikova B, Bortlicek Z, Halamkova J, Ostrizkova L, Kiss I, Melichar B, Pavlik T, Dusek L, Valik D, Vyzula R, Zdrazilova-Dubska L.

BMC Gastroenterol. 2015 Mar 24;15:37. doi: 10.1186/s12876-015-0266-6.

14.

Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.

Bennouna J, Borg C, Delord JP, Husseini F, Trillet-Lenoir V, Faroux R, François E, Ychou M, Goldwasser F, Bouché O, Senellart H, Kraemer S, Douillard JY.

Clin Colorectal Cancer. 2012 Mar;11(1):38-44. doi: 10.1016/j.clcc.2011.05.002. Epub 2011 Jul 29.

PMID:
21803002
15.

Efficacy and safety of bevacizumab in Chinese patients with metastatic colorectal cancer.

Zhu LM, Zhao YZ, Ju HX, Liu LY, Chen L, Liu BX, Xu Q, Luo C, Ying JE, Yang YS, Zhong HJ.

Asian Pac J Cancer Prev. 2014;15(16):6559-64.

16.

Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels.

Kim S, Dobi E, Jary M, Monnien F, Curtit E, Nguyen T, Lakkis Z, Heyd B, Fratte S, Cléau D, Lamfichekh N, Nerich V, Guiu B, Demarchi M, Borg C.

BMC Cancer. 2013 Dec 27;13:611. doi: 10.1186/1471-2407-13-611.

17.

Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor-targeting agents.

Cetin B, Kaplan MA, Berk V, Ozturk SC, Benekli M, Isıkdogan A, Ozkan M, Coskun U, Buyukberber S.

Asian Pac J Cancer Prev. 2012;13(3):1059-63.

18.

The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801).

Nakayama G, Uehara K, Ishigure K, Yokoyama H, Ishiyama A, Eguchi T, Tsuboi K, Ohashi N, Fujii T, Sugimoto H, Koike M, Fujiwara M, Ando Y, Kodera Y.

Cancer Chemother Pharmacol. 2012 Oct;70(4):575-81. Epub 2012 Aug 12.

19.

Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer.

Park LC, Lee HS, Shin SH, Park SJ, Park MI, Oh SY, Kwon HC, Baek JH, Choi YJ, Kang MJ, Kim YS.

World J Gastroenterol. 2012 Mar 14;18(10):1104-9. doi: 10.3748/wjg.v18.i10.1104.

20.

Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.

Modest DP, Reinacher-Schick A, Stintzing S, Giessen C, Tannapfel A, Laubender RP, Brodowicz T, Knittelfelder R, Vrbanec D, Schmiegel W, Heinemann V, Zielinski CC.

Anticancer Drugs. 2012 Jul;23(6):666-73. doi: 10.1097/CAD.0b013e328352ff1d.

PMID:
22441566

Supplemental Content

Support Center